To explore the role of 4D PET-CT in radiation treatment planning, relative to standard 3D PET-CT.
ID
Source
Brief title
Condition
- Gastrointestinal neoplasms malignant and unspecified
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The estimation of tumor size of the primary esophageal tumor on 4D vs 3D FDG
PET.
Secondary outcome
Measurement of SUV max, SUV mean, and SUV peak in 4D versus 3D images of
esophageal cancer and lymph nodes and number of suspected involved lymph nodes.
Background summary
FDG PET-CT image acquisition in the abdominal and thoracic region is influenced
by organ motion. Respiratory movement blurs the metabolic signal of the
esophageal tumor and lymph nodes. We hypothesize that the metabolic signal
obtained with motion compensation results in higher SUV-max values and clearer
demarcation of the esophageal tumor and lymph nodes.
Study objective
To explore the role of 4D PET-CT in radiation treatment planning, relative to
standard 3D PET-CT.
Study design
A pilot study
Intervention
Patients will be imaged with 4D-CT images in addition to the normal protocol of
FDG PET-CT image acquisition.
Study burden and risks
For patients, the total radiation burden per PET scan combined with low dose CT
images is about 10 mSv. The addition of 4D CT scan adds 50mSv to the total
scan. If patients subsequently receives curative chemoradiotherapy, about
0.5-1.0% of the delivered radiation dose to the tumour is inadvertently given
to locations near the tumour region. Due to this, the dose directly outside the
treated region is about 200-400 mSv due to the treatment of 41.4 Gy
radiotherapy. Therefore, the dose increase of 50 mSv due to 4D CT is
negligible. Secondary risks associated with radiation exposure are not
increased considerably.
Patients that are not eligible for chemoradiotherapy will have distant
metastases with a short life expectancy. Therefore, secondary cancer risk from
increased radiation exposure is not an issue.
Plesmanlaan 121
Amsterdam 1066CX
NL
Plesmanlaan 121
Amsterdam 1066CX
NL
Listed location countries
Age
Inclusion criteria
- Patients with pathology proven esophageal cancer or tumor highly suspicious for esophageal cancer
- >= 18 years
- Wtitten informed consent
Exclusion criteria
- <18 years
- Possibility of pregnancy
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL50007.031.14 |